Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoScorch HN: Neoadjuvant Chemotherapy and PD-1 Inhibition for Head and Neck Cancer
NCT07209189Phase 2Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Feb 2026
- Primary completion
- Oct 2030
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in head and neck cancer (HNC), squamous cell carcinoma (SCC), Sinonasal cancer, skull base tumor, sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Feb 2026; status: recruiting.
02
Drugs
toripalimab
03
Conditions
head and neck cancer (HNC)squamous cell carcinoma (SCC)Sinonasal cancerskull base tumor
Beyond the preview
Go deeper on NCT07209189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07209189.